0001474064-12-000073.txt : 20121221
0001474064-12-000073.hdr.sgml : 20121221
20121221160249
ACCESSION NUMBER: 0001474064-12-000073
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121221
FILED AS OF DATE: 20121221
DATE AS OF CHANGE: 20121221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nader Francois
CENTRAL INDEX KEY: 0001365343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 121281484
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2012-12-21
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001365343
Nader Francois
550 HILLS DRIVE
BEDMINSTER
NJ
07921
1
1
0
0
President, CEO and Director
Stock Options
3.34
2012-12-21
4
A
0
108000
0
A
2020-02-19
Common Stock
108000
108000
D
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On December 21, 2012, the performance criteria for 108,000 of these options was satisfied when the FDA unanimously voted to approve the NDA for GATTEX for the treatment of SBS. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
/s/ Francois Nader, by Edward Stratemeier as attorney-in-fact
2012-12-21